15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
- 18 January 2023
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 41 (3) , 546-554
Abstract
The treatment of patients with refractory and/or relapsed (R/R) high‐risk myelodysplastic syndrome (HR‐MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL‐2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR‐MDS receiving combination azacytidine (AZA) plus 15‐days duration of venetoclax (VEN‐15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment‐emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real‐world experience of treating R/R MDS with AZA plus VEN‐15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN‐15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease‐burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN‐15d in R/R MDS warrant further prospective evaluation in clinical trials.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LQ20H080003)
- National Natural Science Foundation of China (81970117, 81800121)
This publication has 13 references indexed in Scilit:
- Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceLeukemia & Lymphoma, 2020
- Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective studyLeukemia Research, 2020
- How I treat MDS after hypomethylating agent failureBlood, 2019
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaHaematologica, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patientsLeukemia, 2015
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesLeukemia, 2014
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 2010
- The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDSBlood, 2000